Therefore, in this work, the PMIA formalism backed by AlphaLarge appears to pave the way for the new therapeutics to stop the progression of PD by offering the new structural insight of the causal interaction of Syn-1 with mutated a-Syn. This evidence concerns the gene SYN1 and Parkinson disease.